McElree, I.M.; Packiam, V.T.; Steinberg, R.L.; Hougen, H.Y.; Abou Chakra, M.; Mott, S.L.; O’Donnell, M.A.
Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma. Cancers 2024, 16, 4126.
https://doi.org/10.3390/cancers16244126
AMA Style
McElree IM, Packiam VT, Steinberg RL, Hougen HY, Abou Chakra M, Mott SL, O’Donnell MA.
Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma. Cancers. 2024; 16(24):4126.
https://doi.org/10.3390/cancers16244126
Chicago/Turabian Style
McElree, Ian M., Vignesh T. Packiam, Ryan L. Steinberg, Helen Y. Hougen, Mohamad Abou Chakra, Sarah L. Mott, and Michael A. O’Donnell.
2024. "Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma" Cancers 16, no. 24: 4126.
https://doi.org/10.3390/cancers16244126
APA Style
McElree, I. M., Packiam, V. T., Steinberg, R. L., Hougen, H. Y., Abou Chakra, M., Mott, S. L., & O’Donnell, M. A.
(2024). Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma. Cancers, 16(24), 4126.
https://doi.org/10.3390/cancers16244126
